Articles tagged "IVIG"

2016 American Transplant Congress
Impact of the New Kidney Allocation System (KAS) on Transplant Rates & Outcomes in Broadly-HLA Sensitized (HS) Patients Transplanted After Desensitization (DES).
A. Vo,¹ X. Zhang,² S. Williamson,¹ K. Myers,¹ N. Reinsmoen,² J. Choi,¹ J. Kahwaji,¹ A. Peng,¹ R. Villicana,¹ S. Jordan.¹
¹Kidney Transplant, Cedars-Sinai Medical Center, LA, CA; ²HLA Laboratory, Cedars-Sinai Medical Center, LA, CA.
Introduction: HS patients not desensitized (DES) receiving transplants are at risk for ABMR. DES improves transplant rates, but is limited to donor availability. Implementation of…
2016 American Transplant Congress
Incidence & Impact of De Novo DSA (dnDSA) Formation on Transplant Outcomes in HLA-Sensitized (HS) Patients Transplanted After IVG+Rituximab Desensitization (DES).
A. Vo,¹ J. Choi,¹ J. Kahwaji,¹ J. Mirocha,² A. Peng,¹ R. Villicana,¹ S. Jordan.¹
¹Kidney Transplant, Cedars-Sinai Medical Center, LA, CA; ²Research Institute, Cedars-Sinai Medical Center, LA, CA.
Introduction: Highly-HLA sensitized patients are at risk for developing donor specific antibodies (DSA) & ABMR post-transplant (tx). However, incidence and risk of acute rejections (AR)…
2016 American Transplant Congress
Sequential Analysis of Donor-Specific Antibodies and Pathological Findings Using Intravenous Immunoglobulin in a Highly Sensitized Rat Kidney Transplant Model.
Y. Sawada,¹ K. Omoto,² N. Kohei,⁴ K. Kawanishi,³ M. Okumi,² H. Ishida,² T. Kazunari.²
¹Urology, Fukushima Rosai Hospital, Iwaki, Japan; ²Urology, Tokyo Women's Medical University, Tokyo, Japan; ³Pathology, Tokyo Women's Medical University, Tokyo, Japan; ⁴Urology, Shizuoka General Hospital, Shizuoka, Japan.
Intravenous immunoglobulin (IVIG) has evolved widespread use for treatment of acute antibody-mediated rejection (AAMR) and desensitization in highly HLA-sensitized patients. However, sequential change of the…
2016 American Transplant Congress
Utilization of Plasmapheresis and High Dose of Immunoglobulins in the Treatment of the High Level of De Novo Donor Specific Antibodies for the Successful Islet Allotransplantation.
J. Solomina,¹ Z. Tekin,¹ S. Matosz,¹ K. Golab,¹ C. Thomas,² J. Golebiewska,³ S. Ramachandran,¹ L. Schenck,¹ W. Chon,¹ M. Tibudan,¹ N. Marek-Trzonkowska,⁴ J. Millis,¹ P. Witkowski.¹
¹Surgery, University of Chicago, Chicago, IL; ²Medicine, University of Chicago, Chicago, IL; ³Internal Medicine, Medical University of Gdansk, Gdansk, Poland; ⁴Family Medicine, Medical University of Gdansk, Gdansk, Poland.
Background.Development of donor specific antibodies (DSA) after islet transplantation has been a poor prognostic factor for graft survival, while no intervention is implemented. Here, we…
2016 American Transplant Congress
Transient Hepatitis B Core Positivity After Administration of IVIG for Desensitization (DES).
A. Nejad, A. Vo, J. Choi, S. Jordan.
Kidney Transplant, Cedars-Sinai Medical Center, LA, CA.
INTRODUCTION: IVIG has become an essential tool in the treatment of sensitized patients prior to solid organ transplantation and is routinely used to treat viral…
2016 American Transplant Congress
EBV Sero-Positivity Does Not Reduce the Risk for EBV Viremia and/or Post-Transplant Lymphoproliferative Disorder (PTLD) in Patients (Pts) Receiving Belatacept (CTLA4Ig).
J. Choi, B. Shin, J. Kahwaji, S. Ge, D. Thomas, A. Vo, O. Galera, R. Villicana, A. Peng, S. Jordan, M. Toyoda.
Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA.
Introduction: CTLA4Ig is a novel immunosuppressive (IS) which acts through costimulatory blockade of T-cells and obviates the need for calcineurin inhibitor-based IS (CNI-IS). Despite benefits…
2015 American Transplant Congress
Extended Analysis of Tocilizumab (anti-IL-6R) + Intravenous Immunoglobulin (IVIG) as Desensitization (DES) Agents for Reduction of Donor Specific Antibodies (DSA) in Patients Resistant to DES With IVIG + Rituximab
A. Vo, J. Choi, I. Kim, J. Kahwaji, A. Peng, R. Villicana, S. Jordan.
Kidney Transplant, Cedars-Sinai Medical Center, Los Angeles, CA.
Introduction: IVIG+rituximab is an acceptable approach for DES with good outcomes. Despite this, ∼30% of patients fail DES, thus other approaches are needed. Options include…
2015 American Transplant Congress
Long-Term Analysis of a Placebo-Controlled Trial of C1-INH for Prevention of Antibody-Mediated Rejection
A. Vo, J. Choi, J. Kahwaji, D. Puliyanda, A. Peng, R. Villicana, S. Jordan.
Kidney Transplant, Cedars-Sinai Medical Center, Los Angeles, CA.
Introduction: Desensitization (DES) strategies focus primarily on antibody reduction using IVIG, rituximab ± PLEX to prevent DSA-induced antibody-mediated rejection (ABMR) and rebound B-cell activity. Recently,…
2015 American Transplant Congress
De Novo Donor Specific Antibody (DSA) After Treatment of BK Infection With Intravenous Immunoglobulin (IVIG)
J. Kahwaji, P. Wongsaroj, J. Choi, A. Peng, R. Villicana, S. Jordan, A. Vo.
Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA.
Introduction: The primary treatment for polyomavirus BK viral infection (BKV) is a reduction in immunosuppression exposure. However this can lead to rejection and development of…
2015 American Transplant Congress
Should Current IVIg Preparations Containing High Titers of Anti-HLA-I/-II IgG be Used for Lowering the Anti-HLA IgG in Sensitized Pre-Transplant Patients and Allograft Recipients?
M. Ravindranath, P. Terasaki, C. Maehara, V. Jucaud.
HLA antibodies, Terasaki Foundation Laboratory, Los Angeles, CA.
Sera of non-alloimmunized individuals contain anti-HLA-I & -II IgG. Therefore it is reasonable expect HLA-I/-II reactivity of Intravenous Immunoglobulin (IVIg). However, the titers at which…